

EEA1 RABBIT PAB

Cat.#: S215698

Product Name: Anti-EEA1 Rabbit Polyclonal Antibody

Synonyms: MST105; ZFYVE2; MSTP105

UNIPROT ID: Q15075 (Gene Accession - NP_003557)

Background: Enables 1-phosphatidylinositol binding activity; GTP-dependent protein binding activity; and protein homodimerization activity. Involved in endocytosis; vesicle fusion; and viral RNA genome replication. Located in cytosol and early endosome. Is extrinsic component of plasma membrane.

Immunogen: Synthetic peptide of human EEA1

Applications: ELISA, WB, IHC

Recommended Dilutions: IHC: 50-200;WB: 1000-5000;ELISA: 5000-10000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG


Purification: Antigen affinity purification

Species Reactivity: Human, Mouse


Constituents: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Signal Transduction, Neuroscience


Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 215698 (EEA1 Antibody) at a dilution of 1/50 (Cytoplasm).




In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 215698 (Anti-EEA1 Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using 215698 (Anti-EEA1 Antibody) at a dilution of 1/50.



In comparison with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with synthetic peptide and then with D163757 (Anti-EEA1 Antibody) at dilution 1/50.



Gel: 6% SDS-PAGE, Lysate: 40 µg;
Lane 1-3: 293T, HeLa, HepG2 cell lysates;
Primary antibody: 215698 (EEA1 Antibody) at dilution 1/1000;
Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000 dilution;
Exposure time: 90 seconds



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
